Navigation Links
Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
Date:6/22/2008

hese events are key aspects of identifying and minimizing them, Lilly has proposed a plan for managing PDSS risks that is comprised of a detailed product label, extensive healthcare provider training before product availability and an ongoing educational program.

About HGKB (160-week Interim Results of Open-label Extension Trial)

Adult patients with schizophrenia or schizoaffective disorder (n=931) were enrolled in this ongoing open-label trial of olanzapine LAI following participation in one of three randomized, controlled studies of olanzapine LAI. At study onset, patients received flexibly-dosed olanzapine LAI at intervals of approximately two to four weeks.

At the time of analysis, all patients had had the opportunity to be in the study for at least one year of open-label treatment; some had been enrolled for up to three years of treatment.

Treatment response was measured by the Clinical Global Impression Severity of Illness (CGI-S) scale, which examined severity of illness, global improvement and efficacy. Baseline-to-endpoint mean change on the CGI-S was -0.16, from a baseline of 2.92.

At 160 weeks, the discontinuation rate was low (39.6 percent). The most common reasons for discontinuation were that a patient withdrew consent (20.1 percent), experienced an adverse event (6.3 percent) or was lost to follow up (5.6 percent).

Adverse events reported in 5 percent or more of patients were increased weight, insomnia, somnolence, anxiety, headache, and nasopharyngitis. The mean weight change of study participants was an increase of 1.4 kilograms, with 28.1 percent of patients experiencing an increase of 7 percent or more in weight.

The percentage of patients with a fasting glucose increase from normal to high at any time was 4.7 percent. The percentage of patients with a random total cholesterol increase from normal to high at any time was 5.2 percent. The percentage of patients with a random triglycerides increase fr
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
2. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
3. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
4. New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
5. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
6. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
7. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
8. New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data
9. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
10. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
11. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014  Diplomat, the nation,s largest independent specialty ... to the Board of Directors on September 15, ... also serve as chair of the Audit Committee. ... accounting, financial, compliance and operating experience in the health ... as chief financial officer, chief operating officer and secretary ...
(Date:9/19/2014)... According to market research ... Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, Surgical ... & Geography - Global Trends & Forecast to ... lyophilization market on the basis of various types, ... the market size of each of these segments ...
(Date:9/19/2014)... -- BioSpecifics Technologies Corp. (NASDAQ: BSTC ), a biopharmaceutical ... ® in the U.S. and XIAPEX ® in ... , will present a corporate overview at the 21 st ... The presentation will take place on Friday, September ... Hotel in New York, NY . A ...
Breaking Medicine Technology:David Dreyer Appointed to Diplomat Board of Directors 2Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2
... a quadriplegic triathlete, has been named spokesperson for National ... with disabilities to live active, mobile lifestyles. The goal ... well as the many other transportation solutions that can ... those with disabilities. Savicki is a proud partner along ...
... In the Middle East and North Africa ... MENA region are among the top 10 globally with the ... Bahrain, Egypt, Kuwait, Oman and Saudi Arabia. The region spends ... its total health care expenditure and expenditure averages as high ...
Cached Medicine Technology:69-Time Gold Medalist and Multi-Sport Wheelchair Athlete Named Spokesperson for National Mobility Awareness Month 269-Time Gold Medalist and Multi-Sport Wheelchair Athlete Named Spokesperson for National Mobility Awareness Month 3Meeting of the Region's Top Diabetes Experts in Dubai this March 2
(Date:9/20/2014)... "As a nurse, patients always ask me ... inventor from Tamaqua, Pa. "The reason that they cannot tell ... their chairs. My invention enables them to check oxygen levels ... to make it easier to monitor the contents of an ... the tank is low. It allows changeovers to be performed ...
(Date:9/20/2014)... 2014 Earlier this week, Home Depot revealed ... had their credit card information pilfered by hackers, surpassing the ... of headline articles like this one published by ... opening numbers. , “Most people tend to focus on ... a way to score a game,” says Joe Caruso, founder ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 Final Cut ... announced the release of the Information theme for FCPX filmmakers. ... use to describe the Information theme,” says Christina Austin, CEO ... to look so professional.” , Information features easy to use ... parameters of the environment. Change the background color, color of ...
(Date:9/20/2014)... “Motherhood is a wonderful gift and a huge responsibility,” ... article , “We know that you want to care for ... want to do as well.” , The article explains to ... their Family Physicians who practice obstetrics while pregnant, during delivery, ... To learn more about Community Health Center of Snohomish County ...
(Date:9/19/2014)... Nearly 780 Risperdal lawsuits are moving forward in ... took place to discuss the next steps in ... mass tort program. Attorneys for the plaintiffs and defendants ... Complex Litigation Center in Philadelphia’s City Hall where the ... lawsuits filed against Johnson & Johnson and its subsidiary, ...
Breaking Medicine News(10 mins):Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5Health News:Today Pixel Film Studios Announced the Release of the Information Theme for Final Cut Pro X 2Health News:Newest Article from Community Health Center of Snohomish County Highlights The Importance of Proper Health Care for Expectant Mothers 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 3Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 4
... researchers at Duke University Medical Center and the Universit catholique ... important energy source for tumor cells. In further experiments, they ... tumor cells by preventing them from delivering lactic acid. ... that low-oxygen, or hypoxic, cells cause resistance to radiation therapy," ...
... Therapeutics Inc., a leader,in the development of predictive ... funding to expand the development and commercialization of,ChemoFx(R). ... physicians select the,most effective chemotherapeutic regimen for cancer ... the round and was joined by existing,investors Adams ...
... ALEXANDRIA, Va., Nov. 20 Yesterday, America,s Health Insurance ... decided to support an "individual mandate," which requires everyone ... with "guaranteed issue," meaning that everyone must be accepted ... , But the Council for Affordable Health ...
... KANSAS CITY, Mo., Nov. 20 An investor group in ... developer and manufacturer of,diagnostic products whose shares are traded in ... Clint Severson has joined the company,s,board of directors. , ... Reidy stated, "We are delighted that Clint has,agreed to serve ...
... relatives at risk for hospital visits of their own , , ... care for a loved one with Alzheimer,s results in 25 ... or hospital visit every six months, says an Indiana University ... of an Alzheimer,s patient is difficult, but the Indiana University ...
... infection that can cause meningitis, pneumonia in young children, ... officials said Thursday that a shortage of vaccine is ... most important causes of bacterial illness in young children. ... increase in cases, the stepped-up surveillance was prompted by ...
Cached Medicine News:Health News:Lactic acid found to fuel tumors 2Health News:Precision Therapeutics Secures $43 Million in Venture Capital Funding 2Health News:Precision Therapeutics Secures $43 Million in Venture Capital Funding 3Health News:CAHI Stands by Its Principles for Health Insurance Reform 2Health News:Investor Group Commends Clint Severson for Joining Trinity Biotech's Board of Directors 2Health News:When the Caregiver Becomes the Patient 2Health News:CDC Monitors Shortage of Hib Vaccine 2Health News:CDC Monitors Shortage of Hib Vaccine 3
Thru cut kerrison style punch 30 deg, 2.75 X 1.4 mm cut, 110 working length....
6 mm, 45 degree upwards, detachable....
Aaron 2250 is a multipurpose electrosurgical generator with monoploar and bi-polar functions....
Sabre 180 is a powerful niche generator....
Medicine Products: